Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHV01 in healthy adults for Marburg virus
NCT06265012Phase 1Completed
- Sponsor
- Public Health Vaccines LLC
- Start
- Feb 2024
- Primary completion
- Sep 2024
- Modality
- Live Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of rVSVΔG-MARV (Angola) GP in Marburg virus disease (MVD) (4 arms), sponsored by Public Health Vaccines LLC. Primary endpoints: Solicited Adverse Events at 15 days, Unsolicited Adverse Events at 29 days and 3 more. Started Feb 2024; status: completed.
02
Drugs
rVSVΔG-MARV (Angola) GP
03
Conditions
Marburg virus disease (MVD)
Beyond the preview
Go deeper on NCT06265012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06265012.